Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simufilam Food Effect and Bioequivalence Study
NCT04932655Phase 1Completed
- Sponsor
- Cassava Sciences
- Start
- May 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of simufilam in Alzheimer's disease (AD) (4 arms), sponsored by Cassava Sciences. Primary endpoints: Maximum Plasma Concentration at 24 hours, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 24 hours and 1 more. Started May 2021; status: completed.
02
Drugs
simufilam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04932655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932655.